Hey – We’ve released new content on stem cell markets that we are excited to share with you. Let me know what you think.
Top 10 Differentiators for Axiogenesis within the Global iPSC Marketplace
Founded in 2001 in Cologne, Germany, Axiogenesis initially focused on generating mouse embryonic stem cell derived cells and assays. After Yamanaka’s groundbreaking iPSC technology became available, Axiogenesis was the first European company to license and adopt Yamanaka’s iPSC technology in 2010. Now Axiogenesis specializes in human iPSC products, including in vitro models of healthy and diseased cell types and tissues. There are a number of key differentiators that give Axiogenesis a strong position within the global marketplace for iPSC-derived cells and tissues, ten of which are covered here.
Can New Manufacturing Platform Reduce “Sky High” Costs of Stem Cell Therapies?
Recently, the LA Times released an article highlighting the mounting evidence that stem cell treatments will be some of the highest priced treatments within the medical marketplace. Titled “Sky-high price of new stem cell therapies is a growing concern,” the author Michael Hiltzik explores the often exorbitant costs associated with stem cell procedures. Because the manufacturing process substantially impacts the final cost of a stem cell therapy, economically manufacturing stem cells will be a critical step forward.
Comparison of the Top 3 International Cord Blood Banks – Cryo-Save, CryoHoldco, China Cord Blood Corporation
In this article, we compare the three largest international cord blood banks. The metrics used to identify the top three were the number of cord blood and cord tissue units stored, number of transplants, rate of growth, and regions served. The three companies identified as the market leaders in this analysis were Cryo-Save, CryoHoldco, and China Cord Blood Corporation (CCBC). If you are competing in the global cord blood banking marketplace, you need to read this analysis.
Could NiCord® Introduce a Paradigm Shift to HSCT? Gamida Cell Presents Phase 1/2 Study Results at ASCO 2016
Gamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. Its lead product, NiCord®, offers patients in need of hematopoietic stem cell transplantation (HSCT) an alternative to the existing approach of bone marrow transplant by using ex vivoexpansion of cord blood. At ASCO 2016, Gamida Cell presented results from its international, multi-center, Phase 1/2 study of NiCord® that demonstrate statistically significant improvements across key measures, including time to engraftment of neutrophils and platelets.
High-Volume 3D Printing of Living Stem Cells – Proof-of-Concept Established by Nano Dimension and Accellta
Nano Dimension announced it has successfully lab-tested a proof-of-concept 3D bioprinter for stem cells in collaboration with Accellta. Nano Dimension specializes in 3D printing systems, while Accellta uses 3D bioreactors to grow large numbers of cells in suspension. Accellta can increase a cell population from 1 million cells to 10 billion cells in two weeks with an overall cost of about $3,000, by using bioreactors to do it in a very efficient way. Therefore, Accellta’s manufacturing technology could revolutionize the use of stem cells within 3D printing applications by allowing for high-throughput bioprinting.
[Global Strategic Report] “Stem Cell Research Products – Opportunities, Tools, & Technologies”
Recently released, this global strategic report uses 10-years of historical data to identify high-growth areas by stem cell type. Because the stem cell market is rapidly changing, it analyzes leading competitors, presents 2016 market size determinations with projections through 2020, and reveals trend rate data for stem cell scientific publications, grants, clinical trials, and patents. A distinctive feature of this report is an end-user survey of 289 stem cell researchers. Use it to approach institutional investors for fundraising, increase sales from stem cell products, and identify lucrative areas for new product development.
President/CEO of BioInformant.com
“1st and Only Market Research Firm to Specialize in the Stem Cell Industry”
p.s. Have an important stem cell announcement to share? Hit “reply” to this email to reach me.
p.p.s. Will you be attending the “iPSC Derived Cells & Assays Come of Age” User Symposium on June 13 in Boston, Massachusetts? I hope to see you there.
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.